The briefing
At ESMO 2026, MDT‑BRIDGE data showed that early clearance of circulating tumor DNA after durvalumab plus chemotherapy correlated with pathological complete response and favorable outcomes in stage II–III non‑small cell lung cancer. The findings support ctDNA as a potential early response biomarker in neoadjuvant therapy.
Original headline
BRIDGE: Early ctDNA Clearance Predicts Pathological Response and Favorable Outcomes in Stage II–III NSCLC